RxDoctor Payments Data

Megan Maddox, MD

Internal Medicine · Houston, TXNPI 1720422884

Payments from drug & device makers

$15,843in general payments, 2019–2025

Across 959 payments — averaging $16.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$2K
  • Amgen$2K
  • Lilly USA, LLC$1K
  • AstraZeneca$849
  • Pfizer$664
  • plus $8K from 54 others

What the payments were for

  • Food & beverage$15,834100%
  • Education$90%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)113$1,807
Novo Nordisk107$1,767
Amgen114$1,711
Lilly USA, LLC75$1,104
AstraZeneca(2 entities)46$849
Pfizer35$664
Novartis27$569
GSK27$560
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC38$552
Radius Health, Inc.33$427
Amarin Pharma, Inc.28$403
Boehringer Ingelheim23$361
Takeda Pharmaceuticals U.S.A., Inc.20$348
Gilead20$340
Teva Pharmaceuticals USA, Inc.20$323
Dexcom, Inc.14$305
Sanofi-aventis U.S. LLC14$257
UCB, Inc.9$244
Kowa Pharmaceuticals America, Inc.16$233
Merck25$230
Exact Sciences12$226
IBSA Pharma Inc.15$217
Astellas Pharma US Inc11$195
Argenx US, Inc.6$176
Abbott9$175
Biohaven Pharmaceutical Holding Company Ltd.9$139
Otsuka America Pharmaceutical, Inc.8$129
Viiv Healthcare Company6$115
Johnson & Johnson8$103
Corcept Therapeutics5$93
Bayer5$90
Axsome Therapeutics, Inc.4$84
Insulet Corporation4$77
Sunovion Pharmaceuticals Inc.6$76
Neurocrine Biosciences, Inc.4$70
Eisai Inc.4$70
Aimmune Therapeutics, Inc.3$64
Optinose US, Inc.3$55
Biohaven Pharmaceuticals, Inc.2$51
Lundbeck LLC2$46
Ascendis Pharma Endocrinology Inc2$43
Dynavax Technologies Corporation3$39
Cequr Corporation2$36
Xeris Pharmaceuticals, Inc.2$35
Halozyme Inc2$33
EMD Serono, Inc.2$32
Vanda Pharmaceuticals Inc.1$31
Tandem Diabetes Care, Inc.1$28
Alvogen Inc1$25
Biogen1$24
E.r. Squibb & Sons, L.L.C.1$22
Nestle Healthcare Nutrition Inc.1$22
Avvisto Therapeutics, LLC1$21
Azurity Pharmaceuticals, Inc.1$19
Medtronic1$18
Antares Pharma, Inc.1$18
Grifols USA, LLC1$18
Ironwood Pharmaceuticals, Inc1$17
Evoke Pharma, Inc.1$16
Scilex Pharmaceuticals Inc.1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,843 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$154,508
Medicare patients
250
Services billed
2,700

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide70$92,535
MounjaroTirzepatide60$76,688
EliquisApixaban52$67,488
TrulicityDulaglutide25$40,619
XareltoRivaroxaban19$26,920
Repatha SureclickEvolocumab36$26,252
JardianceEmpagliflozin14$23,078
LinzessLinaclotide14$21,072
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$20,252
GemtesaVibegron15$19,586
JanuviaSitagliptin Phosphate12$17,608
FarxigaDapagliflozin Propanediol11$17,217
MyrbetriqMirabegron14$14,325
PremarinEstrogens, Conjugated21$10,151
Soliqua 100-33Insulin Glargine/Lixisenatide11$8,897

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$1,104$117,30785 claims
Novo NordiskOzempic$1,767$92,53570 claims
PfizerEliquis, Premarin$664$77,63973 claims
Johnson & JohnsonXarelto$103$26,92019 claims
AbbVieLinzess, Synthroid$1,807$25,01660 claims
Boehringer IngelheimJardiance$361$23,07814 claims
GSKTrelegy Ellipta$560$20,25213 claims
MerckJanuvia$230$17,60812 claims
AstraZenecaFarxiga$849$17,21711 claims
Astellas Pharma US IncMyrbetriq$195$14,32514 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$257$8,89711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →